Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice

Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice

Transcriptional and epigenetic alterations occur early in Huntington's disease (HD), and treatment with epigenetic modulators is beneficial in several HD animal models. The drug JQ1, which inhibits histone acetyl-lysine reader bromodomains, has shown promise for multiple cancers and neurodegene...

Full description

Bibliographic Details
Main Authors: Kedaigle, Amanda J (Author), Reidling, Jack C (Author), Lim, Ryan G (Author), Adam, Miriam (Author), Wu, Jie (Author), Wassie, Brook T. (Author), Stocksdale, Jennifer T (Author), Casale, Malcolm S (Author), Fraenkel, Ernest (Author), Thompson, Leslie M (Author)
Other Authors: Massachusetts Institute of Technology. Department of Biological Engineering (Contributor)
Format: Article
Language:English
Published: Oxford University Press (OUP), 2020-06-22T18:43:59Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items